---
document_datetime: 2023-09-21 20:14:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/phelinun-epar-all-authorised-presentations_en.pdf
document_name: phelinun-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6829064
conversion_datetime: 2025-12-28 17:46:11.551877
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

| EU/1/20/1487/001   | PHELINUN   | 50 mg   | Powder and solvent for concentrate for solution for infusion   | Intravenous use   | Powder: vial (glass); Solvent: vial (glass)   | Powder: 50 mg; Solvent: 10 ml (5 mg/ml)   | 1 vial + 1 vial   |
|--------------------|------------|---------|----------------------------------------------------------------|-------------------|-----------------------------------------------|-------------------------------------------|-------------------|
| EU/1/20/1487/002   | PHELINUN   | 200 mg  | Powder and solvent for concentrate for solution for infusion   | Intravenous use   | Powder: vial (glass); Solvent: vial (glass)   | Powder: 200 mg; Solvent 40 ml (5 mg/ml)   | 1 vial + 1 vial   |